Noninvasive imaging of arterial inflammation using FDG-PET/CT

Current Opinion in Lipidology

Volumn 25, Issue 6, 2014, Pages 431-437

  Emami, Hamed ^a   Tawakol, Ahmed ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Atherosclerosis; Imaging; Inflammation; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEW DRUG;

ARTERITIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; FEASIBILITY STUDY; HUMAN; INFLAMMATION; LIMIT OF QUANTITATION; MULTICENTER STUDY (TOPIC); NON INVASIVE PROCEDURE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; APHERESIS; BLOOD; DIAGNOSTIC USE; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; POSITRON EMISSION TOMOGRAPHY; RISK FACTOR; SCINTISCANNING;

ANTI-INFLAMMATORY AGENTS; ARTERITIS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; FLUORODEOXYGLUCOSE F18; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; PLAQUE, ATHEROSCLEROTIC; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 84927643304     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000135     Document Type: Review

References (37)

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
2. Tawakol A, Migrino RQ, Bashian GG, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006; 48:1818-1824.
3. Pedersen SF, Graebe M, Fisker Hag AM, et al. Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun 2010; 31:423-429.
4. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nature Rev 2013; 13:709-721.
5. Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 2013; 62:909-917.
6. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48:1825-1831.
7. Elmaleh DR, Fischman AJ, Tawakol A, et al. Detection of inflamed atherosclerotic lesions with diadenosine-5',5'''-P1,P4-tetraphosphate (Ap4A) and positron-emission tomography. Proc Natl Acad Sci U S A 2006; 103:15992-15996.
8. Hyafil F, Cornily JC, Rudd JH, et al. Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med 2009; 50:959-965.
9. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-386.
10. Rudd JH, Warburton EA, Fryer TD, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002; 105:2708-2711.
11. Rudd JH, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol 2010; 55:2527-2535.
12. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007; 48:35-45.
13. Chen SH, Ho KC, Hsieh PH, et al. Potential clinical role of 18F FDG-PET/CT in detecting hip prosthesis infection: a study in patients undergoing two-stage revision arthroplasty with an interim spacer. Q J Nucl Med Mol Imaging 2010; 54:429-435.
14. Sobic-Saranovic D, Artiko V, Obradovic V. FDG PET imaging in sarcoidosis. Semin Nucl Med 2013; 43:404-411.
15. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med 2008; 49:871-878.
16. Mizoguchi M, Tahara N, Tahara A, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011; 4:1110-1118.
17. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49:1772-1780.
18. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
19. van Wijk D, Sjouke B, Figueroa A, et al. Non-pharmacologic lipoprotein apheresis reduces arterial inflammation in patients with familial hypercholesterolemia: a pilot study. J Am Coll Cardiol 2014. (in press).
20. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel noninvasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378:1547-1559.
21. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089-2099.
22. Abdelbaky A, Corsini E, Figueroa AL, et al. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging 2013; 6:747-754.
23. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370:1702-1711.
24. Fernandez-Ortiz A, Jimenez-Borreguero LJ, Penalvo JL, et al. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. Am Heart J 2013; 166:990-998.
25. Dunphy MP, Freiman A, Larson SM, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification, Journal of nuclear medicine: official publication. J Nucl Med 2005; 46:1278-1284.
26. Wykrzykowska J, Lehman S, Williams G, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009; 50:563-568.
27. Rogers IS, Nasir K, Figueroa AL, et al. Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. JACC Cardiovasc Imaging 2010; 3:388-397.
28. Nitta Y, Tahara N, Tahara A, et al. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging. JACC Cariovasc Imaging 2013; 6:1172-1182.
29. Emami H, Vijayakumar J, Subramanian S, et al. Arterial Inflammation in Rheumatoid Arthritis Correlates With Synovial Activity. JACC Cardiovasc Imaging 2014;7:959-60.
30. Maki-Petaja KM, Elkhawad M, Cheriyan J, et al. Antitumor necrosis factoralpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012; 126:2473-2480.
31. Fifer KM, Qadir S, Subramanian S, et al. Positron emission tomography measurement of periodontal 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation. J Am Coll Cardiol 2011; 57:971-976.
32. Subramanian S, Emami H, Vucic E, et al. High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins. J Am Coll Cardiol 2013; 62:2382-2391.
33. Rominger A, Saam T, Wolpers S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009; 50:1611-1620.
34. Figueroa AL, Abdelbaky A, Truong QA, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013; 6:1250-1259.
35. Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 2014; 383:705-713.
36. Cuhlmann S, Gsell W, Van der Heiden K, et al. In vivo mapping of vascular inflammation using the translocator protein tracer 18F-FEDAA1106. Mol Imaging 2014; 13:1-10.
37. Tahara N, Mukherjee J, de Haas HJ, et al. 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. Nat Med 2014; 20:215-219.